XTANDI (Astellas Pharma Australia Pty Ltd)

XTANDI is indicated for:

• the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence at high-risk for metastasis (high-risk BCR).
• the treatment of patients with metastatic hormone-sensitive prostate cancer.
• the treatment of patients with non-metastatic castration-resistant prostate cancer (see PROSPER, section 5.1 Clinical trials).
• the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated.
• the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.